{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:26:59Z","timestamp":1793676419863,"version":"4.5.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10072-026-09408-3","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:21:16Z","timestamp":1789622476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of age, BMI, and renal function adjustment on interpretation of serum NfL and GFAP in multiple sclerosis progression: a scoping review"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3734-3548","authenticated-orcid":false,"given":"Aziza Shavkatovna","family":"Kadirova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-7911","authenticated-orcid":false,"given":"Gulnora Kutpitdinovna","family":"Rakhmatullaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7199-0310","authenticated-orcid":false,"given":"Javlon Jasur ugli","family":"Salimjonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"5","key":"9408_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E et al (2019) Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 85(5):653\u2013666","journal-title":"Ann Neurol"},{"issue":"9","key":"9408_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, De Stefano N, Freedman MS, Cree BA, Radue EW, Sprenger T et al (2020) Contribution of relapse-independent progression vs relapse-associated worsening to disability in multiple sclerosis. JAMA Neurol 77(9):1132\u20131140","journal-title":"JAMA Neurol"},{"issue":"3","key":"9408_CR3","first-page":"208","volume":"20","author":"D Ontaneda","year":"2021","unstructured":"Ontaneda D, Fox RJ, Chataway J (2021) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 20(3):208\u2013223","journal-title":"Lancet Neurol"},{"issue":"10","key":"9408_CR4","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.3390\/ijms26104704","volume":"26","author":"G Bsteh","year":"2025","unstructured":"Bsteh G, Dal-Bianco A, Krajnc N, Berger T (2025) Biomarkers of progression independent of relapse activity \u2014 can we actually measure it yet? Int J Mol Sci 26(10):4704","journal-title":"Int J Mol Sci"},{"key":"9408_CR5","doi-asserted-by":"publisher","first-page":"1477335","DOI":"10.3389\/fneur.2024.1477335","volume":"15","author":"C Quintanilla-Bord\u00e1s","year":"2024","unstructured":"Quintanilla-Bord\u00e1s C, Cubas-N\u00fa\u00f1ez L, Castillo-Villalba J et al (2024) Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels. Front Neurol 15:1477335. https:\/\/doi.org\/10.3389\/fneur.2024.1477335","journal-title":"Front Neurol"},{"issue":"8","key":"9408_CR6","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","volume":"141","author":"C Barro","year":"2018","unstructured":"Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y et al (2018) Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141(8):2382\u20132391","journal-title":"Brain"},{"issue":"2","key":"9408_CR7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/jnnp-2016-313476","volume":"88","author":"G Disanto","year":"2017","unstructured":"Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T et al (2017) Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 88(2):126\u2013129","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"9408_CR8","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-020-1094-y","volume":"26","author":"K Bjornevik","year":"2020","unstructured":"Bjornevik K, Munger KL, Cortese M, Barro C, Healy BC, Niebuhr DW et al (2020) Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. Nat Med 26(11):1672\u20131677","journal-title":"Nat Med"},{"issue":"9","key":"9408_CR9","first-page":"527","volume":"19","author":"J Kuhle","year":"2023","unstructured":"Kuhle J, Barro C, Willemse EAJ, Disanto G, Benkert P, Mathias A et al (2023) Serum neurofilament light chain: a biomarker for clinical trials and clinical practice in multiple sclerosis. Nat Rev Neurol 19(9):527\u2013540","journal-title":"Nat Rev Neurol"},{"key":"9408_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S et al (2018) Multiple sclerosis. Nat Rev Dis Primers 4:43","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"9408_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"issue":"5","key":"9408_CR12","first-page":"2091","volume":"129","author":"M Absinta","year":"2019","unstructured":"Absinta M, Sati P, Masuzzo F, Nair G, Sethi V, Kolb H et al (2019) Association of chronic active multiple sclerosis lesions with disability. J Clin Invest 129(5):2091\u20132105","journal-title":"J Clin Invest"},{"issue":"3","key":"9408_CR13","first-page":"205521732513727","volume":"11","author":"ED Schilke","year":"2025","unstructured":"Schilke ED, Smith P, Brownlee W, Chard D, Altmann D, Kapoor R et al (2025) Analysis of an innovative fluid biomarker panel for early prediction of progression independent of relapse activity in multiple sclerosis. Mult Scler J Exp Transl Clin 11(3):20552173251372751","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"9408_CR14","first-page":"100679","volume":"31","author":"M Di Filippo","year":"2024","unstructured":"Di Filippo M, Gaetani L, Parnetti L (2024) Fluid biomarkers in multiple sclerosis: from current to future applications. Lancet Reg Health Eur 31:100679","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"9408_CR15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40001-023-01034-5","volume":"28","author":"J Costa","year":"2023","unstructured":"Costa J, Strecker JF, Pinto S, Pronto-Laborinho A, Gromicho M, de Carvalho M (2023) Biomarkers in multiple sclerosis: an update. Eur J Med Res 28(1):86","journal-title":"Eur J Med Res"},{"issue":"6","key":"9408_CR16","first-page":"e202250228","volume":"53","author":"AJ Gill","year":"2023","unstructured":"Gill AJ, Kolb H, Bittner S, Gusho E, Miller L, Lublin F et al (2023) Emerging imaging and liquid biomarkers in multiple sclerosis. Eur J Immunol 53(6):e202250228","journal-title":"Eur J Immunol"},{"issue":"3","key":"9408_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli \u00d6, Maceski A et al (2022) Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 21(3):246\u2013257","journal-title":"Lancet Neurol"},{"issue":"6","key":"9408_CR18","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/acn3.795","volume":"6","author":"MP Sormani","year":"2019","unstructured":"Sormani MP, Haering DA, Kropshofer H, Leppert D, Kundu U, Barro C, Kappos L, Tomic D, Kuhle J (2019) Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Ann Clin Transl Neurol 6(6):1081\u20131089. https:\/\/doi.org\/10.1002\/acn3.795","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"9408_CR19","first-page":"1035","volume":"18","author":"C Bridel","year":"2019","unstructured":"Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cerme\u00f1o JC et al (2019) Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. Lancet Neurol 18(11):1035\u20131048","journal-title":"Lancet Neurol"},{"issue":"7","key":"9408_CR20","first-page":"e827","volume":"95","author":"KM Krysko","year":"2020","unstructured":"Krysko KM, Graves JS, Rensel M, Weinstock-Guttman B, Amezcua L, Gazzola K et al (2020) Association of higher serum neurofilament light chain levels with worse outcomes in multiple sclerosis. Neurology 95(7):e827\u2013e839","journal-title":"Neurology"},{"issue":"1","key":"9408_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.27096","volume":"97","author":"P Benkert","year":"2025","unstructured":"Benkert P, Maleska Maceski A, Schaedelin S, Oechtering J, Melberg S, Barro C et al (2025) Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under B-cell depleting treatment in multiple sclerosis. Ann Neurol 97(1):104\u2013115","journal-title":"Ann Neurol"},{"key":"9408_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70149","author":"M Einsiedler","year":"2025","unstructured":"Einsiedler M, Benkert P, Schaedelin S, Oechtering J, Lorscheider J, Barro C et al (2025) Serum neurofilament light chain in multiple sclerosis: superiority of age- and BMI-corrected Z-scores for prediction of treatment response. Ann Clin Transl Neurol. https:\/\/doi.org\/10.1002\/acn3.70149","journal-title":"Ann Clin Transl Neurol"},{"key":"9408_CR23","doi-asserted-by":"publisher","first-page":"852563","DOI":"10.3389\/fimmu.2022.852563","volume":"13","author":"T Ziemssen","year":"2022","unstructured":"Ziemssen T, Arnold DL, Alvarez E, Cross AH, Havrdova EK, Hartung HP et al (2022) Prognostic value of serum neurofilament light chain for disease activity in relapsing multiple sclerosis. Front Immunol 13:852563","journal-title":"Front Immunol"},{"issue":"10","key":"9408_CR24","first-page":"1298","volume":"30","author":"EAJ Willemse","year":"2024","unstructured":"Willemse EAJ, Benkert P, Schaedelin S, Oechtering J, Melberg S, Lorscheider J et al (2024) Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis. Mult Scler 30(10):1298\u20131308","journal-title":"Mult Scler"},{"issue":"10","key":"9408_CR25","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1177\/1352458521993066","volume":"28","author":"S Thebault","year":"2022","unstructured":"Thebault S, Bose G, Booth R, Freedman MS (2022) Serum neurofilament light in MS: The first true blood-based biomarker? Mult Scler 28(10):1491\u20131497","journal-title":"Mult Scler"},{"issue":"1","key":"9408_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuron.2016.06.030","volume":"91","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H (2016) Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron 91(1):1\u20133","journal-title":"Neuron"},{"key":"9408_CR27","doi-asserted-by":"crossref","first-page":"100782","DOI":"10.1016\/j.lanepe.2023.100782","volume":"36","author":"E Portaccio","year":"2024","unstructured":"Portaccio E, Magyari M, Havrdova EK, Horakova D, Berger T, Izquierdo G et al (2024) Multiple sclerosis: emerging epidemiological trends and future challenges. Lancet Reg Health Eur 36:100782","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"9408_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","volume":"10","author":"I Boutitah-Benyaich","year":"2025","unstructured":"Boutitah-Benyaich I, Eixarch H, Villacieros-\u00c1lvarez J, Espejo C, Montalban X (2025) Multiple sclerosis: molecular pathogenesis and therapeutic perspectives. Signal Transduct Target Ther 10(1):324","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"9408_CR29","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC (2020) Treatment of multiple sclerosis: a review. Am J Med 133(12):1380\u20131390","journal-title":"Am J Med"},{"issue":"3","key":"9408_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier S, Willemse EAJ, Schaedelin S, Oechtering J, Lorscheider J, Melberg S et al (2023) Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol 80(3):287\u2013297","journal-title":"JAMA Neurol"},{"issue":"2","key":"9408_CR31","doi-asserted-by":"crossref","first-page":"e200195","DOI":"10.1212\/NXI.0000000000200195","volume":"11","author":"P Schindler","year":"2024","unstructured":"Schindler P, Hoshi MM, Kuhle J, Benkert P, Oechtering J, Platten M et al (2024) Serum GFAP as a marker of disease progression in primary progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 11(2):e200195","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"9408_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D et al (2018) PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 169(7):467\u2013473","journal-title":"Ann Intern Med"},{"issue":"8","key":"9408_CR33","first-page":"740","volume":"95","author":"T Uher","year":"2024","unstructured":"Uher T, Benkert P, Schaedelin S, Oechtering J, Melberg S, Barro C et al (2024) Serum biomarkers in secondary progressive multiple sclerosis: a longitudinal cohort study. J Neurol Neurosurg Psychiatry 95(8):740\u2013748","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"9408_CR34","first-page":"e210023","volume":"104","author":"J Lorscheider","year":"2025","unstructured":"Lorscheider J, Kuhle J, Izquierdo G, Benkert P, Oechtering J, Melberg S et al (2025) Serum GFAP dynamics and disability worsening in multiple sclerosis: a multicenter cohort study. Neurology 104(2):e210023","journal-title":"Neurology"},{"issue":"1","key":"9408_CR35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00415-024-12738-x","volume":"272","author":"C Gasperi","year":"2025","unstructured":"Gasperi C, Hapfelmeier A, Dorn F, Hemmer B, Biberacher V (2025) Serum neurofilament light chain and glial fibrillary acidic protein in clinically isolated syndrome: prediction of conversion to multiple sclerosis. J Neurol 272(1):45","journal-title":"J Neurol"},{"issue":"1","key":"9408_CR36","doi-asserted-by":"publisher","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","volume":"8","author":"A Abdelhak","year":"2018","unstructured":"Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M (2018) Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep 8(1):14798","journal-title":"Sci Rep"},{"issue":"12","key":"9408_CR37","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1093\/brain\/awae260","volume":"147","author":"E Monreal","year":"2024","unstructured":"Monreal E, Fern\u00e1ndez JI, \u00c1lvarez R, de la Sainz S, Rodr\u00edguez-Mart\u00edn E, Costa-Frossard L et al (2024) Serum biomarkers at disease onset for personalized therapy in multiple sclerosis. Brain 147(12):4084\u20134095","journal-title":"Brain"},{"key":"9408_CR38","doi-asserted-by":"publisher","first-page":"105747","DOI":"10.1016\/j.msard.2024.105747","volume":"89","author":"X Ayrignac","year":"2024","unstructured":"Ayrignac X, Le Bars E, Duflos C, Hirtz C, Maleska Maceski A, Carra-Dalli\u00e8re C et al (2024) Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: a 6-year follow-up. Mult Scler Relat Disord 89:105747","journal-title":"Mult Scler Relat Disord"},{"issue":"13","key":"9408_CR39","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1177\/13524585251375780","volume":"31","author":"S Sandgren","year":"2025","unstructured":"Sandgren S, Maceski AM, Benkert P et al (2025) Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity. Mult Scler 31(13):1531\u20131542. https:\/\/doi.org\/10.1177\/13524585251375780","journal-title":"Mult Scler"},{"issue":"7","key":"9408_CR40","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1007\/s00415-024-12389-y","volume":"271","author":"I Rosenstein","year":"2024","unstructured":"Rosenstein I, Nordin A, Sabir H, Malmestr\u00f6m C, Blennow K, Axelsson M, Novakova L (2024) Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis. J Neurol 271(7):4412\u20134422","journal-title":"J Neurol"},{"key":"9408_CR41","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/acn3.52187","volume":"11","author":"E Madill","year":"2024","unstructured":"Madill E, Healy BC, Molazadeh N, Polgar-Turcsanyi M, Glanz BI, Weiner HL, Chitnis T (2024) Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis. Ann Clin Transl Neurol 11:2719\u20132730. https:\/\/doi.org\/10.1002\/acn3.52187","journal-title":"Ann Clin Transl Neurol"},{"issue":"22","key":"9408_CR42","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","volume":"89","author":"L Novakova","year":"2017","unstructured":"Novakova L, Zetterberg H, Sundstr\u00f6m P, Axelsson M, Khademi M, Gunnarsson M et al (2017) Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology 89(22):2230\u20132237","journal-title":"Neurology"},{"issue":"11","key":"9408_CR43","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1136\/jnnp-2025-335831","volume":"96","author":"A Abdelhak","year":"2025","unstructured":"Abdelhak A et al (2025) Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis. J Neurol Neurosurg Psychiatry 96(11):1046\u20131052. https:\/\/doi.org\/10.1136\/jnnp-2025-335831","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"9408_CR44","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234","journal-title":"N Engl J Med"},{"issue":"3","key":"9408_CR45","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220","journal-title":"N Engl J Med"},{"key":"9408_CR46","doi-asserted-by":"publisher","unstructured":"Calabrese M, Preziosa P, Scalfari A, et al (2024) Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann Neurol 96(1):1\u201320. https:\/\/doi.org\/10.1002\/ana.26913","DOI":"10.1002\/ana.26913"},{"issue":"3","key":"9408_CR47","doi-asserted-by":"crossref","first-page":"fcae172","DOI":"10.1093\/braincomms\/fcae172","volume":"6","author":"R Kapoor","year":"2024","unstructured":"Kapoor R, Smith P, Prados F, Brownlee W, Chard D, Altmann D et al (2024) Combined serum NfL and GFAP for predicting disability progression in multiple sclerosis. Brain Commun 6(3):fcae172","journal-title":"Brain Commun"},{"issue":"5","key":"9408_CR48","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/jnnp-2023-332251","volume":"95","author":"N Fissolo","year":"2024","unstructured":"Fissolo N, Pappolla A, Lopez A, Meca-Lallana V, Rovira A, Rio J et al (2024) Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 95(5):410\u2013418","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9408_CR49","first-page":"102302","volume":"69","author":"MS Freedman","year":"2024","unstructured":"Freedman MS, Gnanapavan S, Booth RA, Calabresi PA, Khalil M, Kuhle J et al (2024) Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EClinicalMedicine 69:102302","journal-title":"EClinicalMedicine"},{"key":"9408_CR50","doi-asserted-by":"publisher","first-page":"105748","DOI":"10.1016\/j.msard.2024.105748","volume":"88","author":"CI Bava","year":"2024","unstructured":"Bava CI, Valentino P, Malucchi S, Bottero R, Martire S, Sapio AD, Bertolotto A (2024) Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions. Mult Scler Relat Disord 88:105748","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"9408_CR51","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1177\/13524585251335521","volume":"31","author":"E Madill","year":"2025","unstructured":"Madill E et al (2025) Change in serum neurofilament light chain and glial fibrillary acidic protein levels with high-efficacy and low-efficacy early therapy in multiple sclerosis. Mult Scler 31(8):944\u2013954","journal-title":"Mult Scler"},{"issue":"9","key":"9408_CR52","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1177\/13524585231176732","volume":"29","author":"X Jiang","year":"2023","unstructured":"Jiang X, Shen C, Teunissen CE et al (2023) Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation. Mult Scler 29(9):1070\u20131079. https:\/\/doi.org\/10.1177\/13524585231176732","journal-title":"Mult Scler"},{"key":"9408_CR53","doi-asserted-by":"publisher","first-page":"106899","DOI":"10.1016\/j.msard.2025.106899","volume":"106","author":"K Kohlhase","year":"2026","unstructured":"Kohlhase K, Grefkes C, Kurt A, Rixe S, \u00d6zt\u00fcrk F, Koenig H et al (2026) Usage and limitations of neuroglial biomarkers NfL and GFAP in urine as non-invasive disease markers in multiple sclerosis. Mult Scler Relat Disord 106:106899","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"9408_CR54","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1515\/revneuro-2020-0145","volume":"32","author":"S Momtazmanesh","year":"2021","unstructured":"Momtazmanesh S, Shobeiri P, Saghazadeh A, Teunissen CE, Burman J, Szilasiov\u00e1 J et al (2021) Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. Rev Neurosci 32(6):573\u2013595","journal-title":"Rev Neurosci"},{"issue":"12","key":"9408_CR55","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","volume":"80","author":"A Abdelhak","year":"2023","unstructured":"Abdelhak A, Benkert P, Schaedelin S, Boscardin WJ, Cordano C, Oechtering J et al (2023) Neurofilament light chain elevation and disability progression in multiple sclerosis. JAMA Neurol 80(12):1317\u20131325","journal-title":"JAMA Neurol"},{"issue":"4S","key":"9408_CR56","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4S):S117\u2013S314","journal-title":"Kidney Int"},{"issue":"10","key":"9408_CR57","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1177\/13524585251360972","volume":"31","author":"N Krajnc","year":"2025","unstructured":"Krajnc N et al (2025) Serum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosis. Mult Scler 31(10):1175\u20131186","journal-title":"Mult Scler"},{"issue":"4","key":"9408_CR58","first-page":"1257","volume":"45","author":"P Olejnik","year":"2024","unstructured":"Olejnik P, Siger M, Stasio\u0142ek M (2024) Multiple sclerosis: a narrative overview of current therapeutic strategies. Neurol Sci 45(4):1257\u20131272","journal-title":"Neurol Sci"},{"issue":"6","key":"9408_CR59","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S1474-4422(24)00140-6","volume":"23","author":"A Haghikia","year":"2024","unstructured":"Haghikia A, Schett G, Mougiakakos D, Bittner S, Kr\u00e4mer J, Meuth SG et al (2024) B cell-targeting CAR-T cells as emerging therapy in multiple sclerosis. Lancet Neurol 23(6):567\u2013579","journal-title":"Lancet Neurol"},{"issue":"2","key":"9408_CR60","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378(2):169\u2013180","journal-title":"N Engl J Med"},{"key":"9408_CR61","doi-asserted-by":"publisher","unstructured":"Filippi M, Amato MP, Avolio C, Gallo P, Gasperini C, Inglese M, Marfia GA, Patti F (2025) Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion. J Neurol 272(2). https:\/\/doi.org\/10.1007\/s00415-025-13140-x","DOI":"10.1007\/s00415-025-13140-x"},{"issue":"12","key":"9408_CR62","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1474-4422(25)00249-2","volume":"24","author":"T Chitnis","year":"2025","unstructured":"Chitnis T, Weiner HL, Cree BAC et al (2025) Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications. Lancet Neurol 24(12):1066\u20131078. https:\/\/doi.org\/10.1016\/S1474-4422(25)00249-2","journal-title":"Lancet Neurol"},{"issue":"6","key":"9408_CR63","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s00415-025-13093-1","volume":"272","author":"MS Freedman","year":"2025","unstructured":"Freedman MS, Abdelhak A, Bhutani MK, Freeman J, Gnanapavan S, Hussain S, Madiraju S, Paul F (2025) The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review. J Neurol 272(6):400. https:\/\/doi.org\/10.1007\/s00415-025-13093-1","journal-title":"J Neurol"},{"issue":"5","key":"9408_CR64","first-page":"890","volume":"63","author":"CE Teunissen","year":"2025","unstructured":"Teunissen CE, Otto M, Willemse EAJ, Parnetti L, Zetterberg H, Kuhle J et al (2025) Standardization of serum NfL and GFAP assays for clinical use in multiple sclerosis. Clin Chem Lab Med 63(5):890\u2013901","journal-title":"Clin Chem Lab Med"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09408-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:02:33Z","timestamp":1793674953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09408-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9408"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09408-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable (review article).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the author(s) used ChatGPT for language polishing and editing assistance. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests. No financial or non\u2011financial relationships with manufacturers of Simoa, Ella, or other immunoassay platforms exist.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"795"}}